Latest Graft-versus-host disease Stories
May brought a major advancement in the science of aging when two Harvard Stem Cell Institute (HSCI) researchers announced their discovery of a protein circulating in the blood of mice and humans that shows potential to be a treatment for age-related heart failure.
An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints.
Studies of stem cell biology and transplant approaches presented today at the 54th Annual Meeting of the American Society of Hematology (ASH) illustrate how the use of advanced modeling techniques is optimizing stem cells to treat patients with blood disorders, as well as the potential of enhanced treatment strategies to improve the success rate of hematopoietic stem cell (HSC) transplantation for these patients.
A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments.
- A poem in which the author retracts something said in an earlier poem.